Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

BioMerieux completes purchase of BioFire

Authored by James Sheppard

The French diagnostic company BioMerieux has completed the purchase of US diagnostic company BioFire Diagnostics for $450m plus BioFire’s net financial debt. The deal is aimed at consolidating BioMerieux’s position as a major player in the infectious disease diagnostics market.

BioFire specialise in producing products which can detect viral and bacterial infections in a single test. BioFire currently manufacturers a number of diagnostic products including its High Multiplex PCR Instrument called FilmArray System. The FilmArray system is approved by the FDA for the detection of 17 respiratory diseases, 3 bacterial pathogens and 100 sepsis causing pathogens. In a statement, BioMerieux stated that FilmArray should be able to detect more than 70 agents responsible for respiratory, GI and blood infections within the next three years. “FilmArray is the only system that makes it possible to detect disease-causing viruses and bacteria using a single reagent,” said Jean-Luc Belingard, chairman and CEO

BioMerieux wants to widen its market share by lowering the manufacturing costs of BioFire’s array panels and using its worldwide distribution network. In-vitro diagnostics for infectious diseases is at the core of BioMerieux’s sales and currently the company makes about 85% of its revenues in this segment of the market. The BioFire acquisition will further bolster BioMerieux’s dominance in the market.

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

Contact Us

   Liftstream Ltd.
67 Grosvenor Street

   Tel: ​+44 (0)20 3178 5864

Register your CV

Apply for sector specific vacancies or request a confidential discussion

Registered in England No: 5009233
VAT: 843679292

Follow Us